Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Marijuana Abuse 2Breast Neoplasms 2Anxiety Disorders 2Sturge-Weber Syndrome 1Solid Tumor 1Prostatic Neoplasms 1Parasomnias 1Pain 1Nausea 1Glioblastoma 1Colonic Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Carcinoma In Situ 1Arthralgia 1

Interventions

Memantine 2lithium sulfate 1lime 1fasudil 1XENP 1595 1Ramipril 1Methylphenidate 1Lithium 1Infliximab 1Ibuprofen 1Exercise 1Cannabidiol 1Behavior Therapy 1Aspirin 1Ashwagandha 1Anticonvulsants 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cognitive Dysfunction × Cannabidiol × Clear all
NCT04447846 2023-05-25

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
11 enrolled 25 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡